Blinatumomab
Checked 2026-09-09
B-ALL: MRD-positive, relapsed/refractory, or consolidation in frontline regimens (E1910, AALL1731)
One cycle
every 42 days × 2 · about 12 weeks in totalComponents
| Drug | Dose | Route | Days | Note |
|---|---|---|---|---|
Blinatumomab Bispecific T-cell engager (CD19×CD3) | 28 µg/day continuous infusion (9 µg/day days 1-7 of cycle 1 in relapsed disease) | IV | D1-28 (672 h infusion) |
Cycles
2 (consolidation) to 5
42-day cycle
Emetogenicity
Minimal (<10%)
G-CSF
Not routine
Notes
- Dexamethasone premedication; hospital admission for the first 3 days of cycle 1 and 2 days of cycle 2 for CRS and neurotoxicity.
Used in
Products
Source
TOWER, NEJM 2017; E1910, NEJM 2024
Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.
Other regimens for these cancers
Inotuzumab ozogamicin
Relapsed or refractory CD22-positive B-ALL
every 21 days
Fludarabine + cyclophosphamide lymphodepletion, then CD19 CAR-T
Relapsed or refractory large B-cell lymphoma (second line if refractory or relapse within 12 months), B-ALL, follicular and mantle cell lymphoma
every 6 days
Imatinib
Chronic-phase CML; adjuvant GIST for 3 years after resection of high-risk tumours; metastatic GIST
every 28 days